Acta Med. 2021, 64: 200-203

https://doi.org/10.14712/18059694.2022.2

Is There a Correlation of TSI Levels and Incidental Papillary Thyroid Carcinoma in Graves Disease? A Review of the Latest Evidence

Christos Damaskosa,b, Nikolaos Garmpisa,c, Dimitrios Dimitroulisc, Georgios Kyriakosd, Evangelos Diamantise

aN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
bRenal Transplantation Unit, Laiko General Hospital, Athens, Greece
cSecond Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
dSeccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Spain
eEndocrinology Unit of Academic Department of Internal Medicine, Agioi Anargyroi General Oncology Hospital, National and Kapodistrian University of Athens, Kifisia, Greece

Received December 25, 2020
Accepted November 14, 2021

References

1. Behar R, Arganini M, Wu TC, et al. Graves’ disease and thyroid cancer. Surgery 1986; 100: 1121–7.
2. Pezzolla A, Marzaioli R, Lattarulo S, et al. Incidental carcinoma of the thyroid. Int J Surg 2014; 12 Suppl 1: S98–102. <https://doi.org/10.1016/j.ijsu.2014.05.041>
3. Ergin AB, Saralaya S, Olansky L. Incidental papillary thyroid carcinoma: Clinical characteristics and prognostic factors among patients with Graves’ disease and euthyroid goiter, Cleveland Clinic experience. Am J Otolaryngol 2014; 35: 784–90. <https://doi.org/10.1016/j.amjoto.2014.04.013>
4. Boutzios G, Kostifa E, Tomara N, et al. The association between the levels of the TSI antibodies and thyroid cancer among patients with Graves’ disease who have undergone total thyroidectomy. Endocrine Abstracts 2019; 63: P784.
5. Menon R, Nair CG, Babu M, Jacob P, Krishna GP. The outcome of papillary thyroid cancer associated with Graves’ disease: A case control study. J Thyroid Res 2018; 2018: 8253094. <https://doi.org/10.1155/2018/8253094> <PubMed>
6. Bradley EI 3rd, Liechty RD. Modified subtotal thyroidectomy for Graves’ disease: A two-institution study. Surgery 1983; 94: 955–8.
7. Wada N, Sugino K, Mimura T, et al. Treatment strategy of papillary thyroid carcinoma in children and adolescents: Clinical significance of the initial nodal manifestation. Ann Surg Oncol 2009; 16: 3442–9. <https://doi.org/10.1245/s10434-009-0673-4>
8. Clayman GL, Shellenberger TD, Ginsberg LE, et al. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 2009; 31: 1152–63. <https://doi.org/10.1002/hed.21079>
9. Pelizzo MR, Merante Boschin I, Toniato A, et al. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol 2008; 33: 359–79.
10. Rosenbaum MA, McHenry CR. Contemporary management of papillary carcinoma of the thyroid gland. Expert Rev Anticancer Ther 2009; 9: 317–29. <https://doi.org/10.1586/14737140.9.3.317>
11. Cobin RH, Gharib H, Bergman DA, et al; Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001; 7: 202–20. <https://doi.org/10.4158/EP.7.3.202>
12. NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma. National Comprehensive Cancer Network. 2017. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf.
13. Gabriele R, Letizia C, Borghese M, et al. Thyroid cancer in patients with hyperthyroidism. Horm Res 2003; 60: 79–83.
14. Stocker DJ, Burch HB. Thyroid cancer yield in patients with Graves’ disease. Minerva Endocrinol 2003; 28: 205–12.
15. Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm Metab Res 2012; 44: 255–62.
16. Hales IB, Mc Elduff A, Crummer P, et al. Does Grave’s disease or thryotoxicosis affect the prognosis of thyroid cancer? J Clin Endocrinol Metab 1992; 75: 886–9.
17. Hancock BW, Bing RF, Dirmikis SM, Munro S, Neal FE. Thyroid carcinoma and concurrent hyperthyroidism. Cancer 1977; 39: 298–302. <https://doi.org/10.1002/1097-0142(197701)39:1<298::AID-CNCR2820390146>3.0.CO;2-C>
18. Chou FF, Sheen-Chen M, Chen YS, Chen MJ. Hyperthyroidism and concurrent thyroid cancer. Int Surg 1993; 78: 343–6.
19. Sakorafas GH, Stafyla V, Kolettis T, Tolumis G, Kassaras G, Peros G. Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease. J Postgrad Med 2007; 53: 23–6. <https://doi.org/10.4103/0022-3859.30323>
20. Costanzo M, Caruso LA, Messina DC, et al. Thyroid microcarcinoma in benign thyroid diseases. Ann Ital Chir 2005; 76: 119–21; discussion 121–2.
21. Orsenigo E, Beretta E, Fiacco E, et al. Management of papillary microcarcinoma of the thyroid gland. Eur J Surg Oncol 2004; 30; 1104–6. <https://doi.org/10.1016/j.ejso.2004.07.021>
22. Klofanda J, Krska Z, Trca S. Total thyroidectomy in malignant goiter, significance and problems. Rozhl Chir 2002; 81: 5–7.
23. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588–93. <https://doi.org/10.1111/j.1365-2265.2005.02389.x>
24. Sugitani I, Fujimoto Y, Yamada K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg 2014; 38: 673–8. <https://doi.org/10.1007/s00268-013-2335-8>
25. Ferrari SM, Fallahi P, Elia G, et al. Thyroid autoimmune disorders and cancer. Semin Cancer Biol 2020; 64: 135–46. <https://doi.org/10.1016/j.semcancer.2019.05.019>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive